Angiotensin-converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumour necrosis factor-α, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 7, 2009, Pages 631-636

  Zhang, Xia ^a   Li, Zhong Zhuan ^a   Liu, Dong Fang ^a   Xu, Xin ^a   Mei, Zhe Chuan ^a   Shen, Wei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme inhibitor; Hepatic steatosis; High fat diet; Insulin resistance; Non alcoholic fatty liver disease; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN RECEPTOR 2; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; GLUCOSE; INSULIN; INTERLEUKIN 6; MESSENGER RNA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CIRCULATION; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FATTY LIVER; GLUCOSE BLOOD LEVEL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER; LIVER HISTOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GENE EXPRESSION REGULATION; INTERLEUKIN-6; MALE; RATS; RATS, WISTAR; RECEPTORS, ADIPONECTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650721353     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05129.x     Document Type: Article

References (39)

1. Angelico F, Ben M, Conti R et al. Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003 18 : 588 94.
2. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Diabetes Metab. 2004 30 : 498 505.
3. Iglesias-Osma MC, Torres MA, Garcia-Barrado MJ, Moratinos J. Adipocytokines: Implications in the prognosis and drug treatment of cardiovascular diseases. Rev. Clin. Esp. 2008 208 : 239 46.
4. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: State of the art? Am. J. Physiol. Heart Circ. Physiol. 2007 292 : H1655 63.
5. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003 423 : 762 9.
6. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005 11 : 183 90.
7. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008 103 : 1 8.
8. Tomiyama H, Motobe K, Zaydun G et al. Insulin sensitivity and endothelial function in hypertension. A comparison of temocapril and candesartan. Am. J. Hypertens. 2005 18 : 178 82.
9. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovasc. Drug Rev. 2004 22 : 189 98.
10. Arulmozhi DK, Kurian R, Bodhankar SL, Veeranjaneyulu A. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. J. Pharm. Pharmacol. 2008 60 : 1167 73.
11. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat. A model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 2005 52 : 313 20.
12. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 : 1313 21.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 19.
14. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 5.
15. Toblli JE, Ferder L, Angerosa I, Stella M, Inserra F. Enalapril prevents fatty liver in nephritic rats. J. Nephrol. 2002 15 : 358 67.
16. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: A new role for the renin-angiotensin system. Antioxid. Redox Signal. 2005 7 : 1346 55.
17. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005 115 : 209 18.
18. Logacheva IV, Shustova EN, Morozova NI. Applicability of fozinopril for correction of basic manifestations of metabolic syndrome in women with arterial hypertension. Ter. Arkh. 2005 77 : 60 4 (in Russian).
19. Simonenko VB, Medvedev IN, Tolmachev VV. Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from arterial hypertension with metabolic syndrome. Klin. Med. 2007 85 : 24 7 (in Russian).
20. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003 42 : 76 81. (Pubitemid 36842239)
21. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000 20 : 1595 9.
22. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001 86 : 1930 5.
23. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004 68 : 975 81.
24. Pagano C, Soardo G, Esposito W et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol. 2005 152 : 113 18.
25. Matsushita K, Yatsuya H, Tamakoshi K et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler. Thromb. Vasc. Biol. 2006 26 : 871 6.
26. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003 112 : 91 100. (Pubitemid 38056380)
27. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001 7 : 941 6.
28. Yilmaz MI, Sonmez A, Caglar K et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 2007 12 : 147 53.
29. Tsuchida A, Yamauchi T, Ito Y et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J. Biol. Chem. 2004 279 : 30 817 22.
30. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005 54 : 117 21.
31. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int. J. Cardiol. 2006 108 : 96 100. (Pubitemid 43324913)
32. Hivert MF, Sullivan LM, Fox CS et al. Associations of adiponectin, resistin, and TNF-α with insulin resistance. J. Clin. Endocrin. Metab. 2008 93 : 3165 72.
33. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005 146 : 3417 27.
34. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003 52 : 2784 9.
35. Kanno K, Tazuma S, Nishioka T, Hyogo H, Chayama K. Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig. Dis. Sci. 2005 50 : 942 8.
36. 1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity 2008 16 : 770 6.
37. Yoda-Murakami M, Taniguchi M, Takahashi K et al. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem. Biophys. Res. Commun. 2001 285 : 372 7.
38. Delaigle AM, Jonas JC, Bauche IB et al. Induction of adiponectin in skeletal muscle by inflammatory cytokines: In vivo and in vitro studies. Endocrinology 2004 145 : 5589 97.
39. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005 54 : 117 21.